Development of a rapid test using a multiplex-bead technology for the differential diagnostics of COVID-19

What are critical parameters for a severe progression of COVID-19? Is it possible, to predict the progression by using a rapid test and thus enable differential diagnostics and treatment of COVID-19 patients?

The project BEAD-Dx addresses these questions. To answer them we want to develop an assay which measures not only the characteristic anti-SARS-CoV-2 antibodies but also other biomarkers relevant for the disease progression thus determining the status of the patient’s immune system. In collaboration with our industrial partners Medipan and PolyAn an already existing multiplex assay will be adapted which is based on peptide or protein modified beads coupled to a fluorescence read-out. A rapid, simultaneous analysis of multiple relevant parameters is supposed to enable accelerated differential diagnostics in COVID-19 cases which in turn supports physicians in the assessment, classification, and prognosis of disease progression and eventually treatment decisions.